Steve holds a PhD in Biochemistry from the Faculty of Medicine at the University of Toronto, Canada. He worked as a medical scientist for 18 years, within both industry and academia, where his research focused on the discovery of new medicines to treat inflammatory disorders and infectious diseases. Steve recently stepped away from the lab and into science communications, where he’s helping make medical science information more accessible for everyone.
Eloxx Pharmaceuticals has announced that it’s now added the approved cystic fibrosis (CF) therapy Kalydeco (ivacaftor) to its global Phase 2 clinical program for ELX-02. Ongoing ELX-02 Phase 2 clinical trials, ... Read more
A soft skin sticker that can rapidly measure chloride levels in sweat, which are elevated in cystic fibrosis (CF) patients, may help avoid delays in diagnosis and treatment associated with ... Read more
Eloxx Pharmaceuticals has acquired Zikani Therapeutics and will expand its research program in ribosomal RNA-targeted therapies, with the goal of treating diseases such as cystic fibrosis (CF) caused by a ... Read more
A precise gene-editing tool that reverses single DNA mutations may lead to genetic therapies for people with cystic fibrosis (CF), a study suggests. The study, “Programmable C:G to G:C genome ... Read more
For the first time, bacteriophage therapy treated a boy with chronic and antibiotic-resistant Achromobacter bacteria infection following a double lung transplant due to cystic fibrosis (CF), a case study reported. ... Read more
The Achromobacter bacteria species that is an increasing source of chronic lung infections in people with cystic fibrosis (CF) shows evidence of patient-to-patient transmission and emerging antibiotic resistance, scientists in ... Read more
Elevated levels of fecal calprotectin protein, a biomarker for intestinal inflammation, was linked to worse gastrointestinal symptoms and quality of life in children with cystic fibrosis (CF), a study reports. ... Read more